TrialJournal of diabetes investigation2020

Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo-controlled double-blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi-center placebo-controlled double-blind randomized trial.

Atsushi Tanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.